Press Releases

Date Title and Summary    
Toggle Summary Rexahn Pharmaceuticals Announces Leadership Transition
Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, Md. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve outcomes in cancers that are difficult to treat, today
View HTML Print
Toggle Summary Rexahn Reports Third Quarter 2018 Financial Results
ROCKVILLE, Md. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the three and nine months ended September 30,
View HTML Print
Toggle Summary Rexahn Announces $7.5 Million Registered Direct Offering
ROCKVILLE, Md. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer
Combination of RX-3117 and Abraxane Appears Safe and Well-Tolerated When Administered at the Recommended Phase 2 Dose of RX-3117 and the Maximal Labeled Dose of Abraxane Preliminary Efficacy was Observed With One Complete Response, Three Partial Responses and Eight Patients With Stable Disease in
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium
Preliminary Safety and Efficacy Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer will be presented ROCKVILLE, Md. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that Peter D. Suzdak , Ph.D., the Company's chief executive
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
ROCKVILLE, Md. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration agreement
View HTML Print
Toggle Summary Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
ROCKVILLE, Md. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter
View HTML Print
Toggle Summary Rexahn Reports Second Quarter 2018 Financial Results
ROCKVILLE, Md. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the second quarter ended June 30, 2018 .
View HTML Print
Toggle Summary Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018
Three of four proposals pass with shareholder approval Annual Meeting adjourned solely with respect to Proposal 3 — approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock ROCKVILLE, Md., June 14, 2018
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy